Transgene SA, a company specializing in immunotherapies, and ABL, Inc., a contract research and manufacturing organization, announced the purchase by ABL Europe, a wholly owned subsidiary of ABL, of Transgene’s production asset situated in Illkirch, France, near Strasbourg. Transgene, ABL and ABL Europe are all three members of the Institut Mérieux. The production asset is designed and equipped to manufacture clinical lots of biophamaceuticals and vaccines using viral vectors. ABL Europe h...